HSPB3 and ovarian cancer: Recent evidence suggested that HSp17 was aberrantly expressed in many malignant tumors, such as multiple myelomas [6], ovarian cancers [7], esophageal squamous cell carcinomas [8], esthesioneuroblastomas [9], and various histological subtypes of human nervous system (NS) malignancies, including neuroectodermal and meningeal tumors [10].